| Cite this article: |
| TANG Yi,YAN Chulin,DAI Xinli,ZENG Yizhen,QU Bangchen,TAO Liang.Research progress on the role of natural compounds in regulating ferroptosis in metabolic associated fatty liver disease[J].Journal Of Pharmaceutical Research,2026,45(1):63-71,102[Click to copy] |
|
| 摘要: |
| 铁死亡作为一种铁依赖性脂质过氧化驱动的程序性细胞死亡形式,在代谢相关脂肪性肝病(metabolic associated fatty liver disease, MAFLD)的病理进程中发挥关键作用。MAFLD以肝脏脂质代谢紊乱为核心特征,其进展与铁过载、脂质过氧化及氧化应激密切相关,而铁死亡调控失衡可进一步加剧肝脏损伤和炎症反应。尽管目前尚无特异性靶向铁死亡的临床药物获批上市,但天然化合物因其多靶点调控特性,展现出了干预铁死亡从而缓解MAFLD的明显潜力。本综述将聚焦天然化合物对铁死亡关键节点与天然化合物的精准调控,结合多项实验性研究,为MAFLD的靶向治疗提供创新策略。 |
| 关键词: 天然化合物 铁死亡 代谢相关脂肪性肝病 |
| DOI:10.13506/j.cnki.jpr.2026.01.010 |
| 基金项目:国家自然科学基金项目(No.82400693);湖南省自然科学基金项目(No.2023JJ40567);南华大学大学生创新创业训练计划项目(No.D202305162239264716) |
|
Publication Date:January 26, 2026
|
|
| Research progress on the role of natural compounds in regulating ferroptosis in metabolic associated fatty liver disease |
| TANG Yi,YAN Chulin,DAI Xinli,ZENG Yizhen,QU Bangchen,TAO Liang |
| (Hengyang Medical School, University of South China, Hengyang 421001, China) |
| Abstract: |
| Ferroptosis is an iron-dependent programmed cell death form driven by lipid peroxidation, plays a pivotal role in the pathogenesis of metabolic associated fatty liver disease(MAFLD). MAFLD is characterized by hepatic lipid metabolism disorder, with disease progression strongly associated with iron overload, lipid peroxidation, and oxidative stress—where the imbalance in ferroptosis regulation could additionally exacerbate hepatic injury and inflammatory responses. Although there are no clinical drugs specifically targeting ferroptosis approved for market currently, natural compounds demonstrate significant potential in intervening ferroptosis to alleviate MAFLD due to their multi-target regulatory properties. This review focuses on precisely regulating key ferroptosis pathways by natural compounds, integrating multiple experimental studies to propose innovative strategies for targeted MAFLD therapy. |
| Key words: Natural compounds Ferroptosis Metabolic associated fatty liver disease |